Caterpillar (CAT) stock has tumbled 22% in the trailing 52-weeks period, battered by the US-China trade tensions. As the company reports its fourth quarter results on Monday, January 28, investors will be looking at how much the manufacturing giant has fended off these external threats.
Analysts’ consensus calls for Q4 earnings at $2.99 per share on revenue of $14.26 billion. This is much higher than last year’s earnings of $2.16 per share on revenue of $12.9 billion. Notably, the maker of mining and construction equipment is currently at a streak of seven back-to-back quarters of revenue and earnings growths, despite the headwinds.
During the last reported quarter, Caterpillar surpassed street estimates but investors were disappointed with the guidance projection. Shares dipped over 3% immediately following the announcement.
The company has been dogged by the material cost inflation stemming out of the metal tariffs that totaled $40 million in Q3. The tariffs are expected to be around $200 million for the whole of 2018. Caterpillar has also been hurt by its significant exposure to the Chinese market, which has been witnessing weakness lately.
To put things into perspective, the whole of the manufacturing industry has been crippled by the trade tensions in 2018. Caterpillar’s stock slump of 22% for the past 12 months is almost in line with the performance of the broader manufacturing industry, which has declined 23%.
On the positive side, the manufacturing behemoth has strong order backlog, which stood at $17.3 billion at the end of the third quarter. Also, the company has been streamlining its operations and increasing its prices to beat the margin compressions. Q4 will drop more hints at how much these measures have been successful.
The stock currently has six Buy ratings and three Hold ratings. It has an average 12-month price target of $155, suggesting a 17% upside from the last close.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
